|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009647,
umls-concept:C0023467,
umls-concept:C0026985,
umls-concept:C0030705,
umls-concept:C0040732,
umls-concept:C0040808,
umls-concept:C0242793,
umls-concept:C0443252,
umls-concept:C0544452,
umls-concept:C1515895,
umls-concept:C1516240
|
|
pubmed:issue |
36
|
|
pubmed:dateCreated |
2005-12-19
|
|
pubmed:abstractText |
The toxicity of allogeneic stem-cell transplantation can be substantially reduced using a reduced-intensity conditioning (RIC) regimen. This has increased the proportion of patients with myeloid malignancies eligible for allogeneic transplantation. However, the capacity of RIC allografts to produce durable remissions in patients with acute myeloid leukemia (AML) and myelodysplasia (MDS) has not yet been defined, and consequently, the role of RIC allografts in the management of these diseases remains conjectural.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BegumGulnazG,
pubmed-author:ChopraRajR,
pubmed-author:CookGordonG,
pubmed-author:CookMarkM,
pubmed-author:CraddockCharlesC,
pubmed-author:GoldstoneAnthonyA,
pubmed-author:HaleGeoffG,
pubmed-author:HunterAnnA,
pubmed-author:JacksonGrahamG,
pubmed-author:KhwajaAsimA,
pubmed-author:LittlewoodTimothyT,
pubmed-author:MackinnonStephenS,
pubmed-author:MahendraPreminiP,
pubmed-author:MarshJudithJ,
pubmed-author:MilliganDonaldD,
pubmed-author:ParkerAnneA,
pubmed-author:PeggsKarlK,
pubmed-author:PeniketAndrewA,
pubmed-author:RussellNigelN,
pubmed-author:TauroSudhirS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
9387-93
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:16314618-Acute Disease,
pubmed-meshheading:16314618-Adolescent,
pubmed-meshheading:16314618-Adult,
pubmed-meshheading:16314618-Aged,
pubmed-meshheading:16314618-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16314618-Disease-Free Survival,
pubmed-meshheading:16314618-Female,
pubmed-meshheading:16314618-Graft vs Host Disease,
pubmed-meshheading:16314618-Humans,
pubmed-meshheading:16314618-Leukemia, Myeloid,
pubmed-meshheading:16314618-Male,
pubmed-meshheading:16314618-Melphalan,
pubmed-meshheading:16314618-Middle Aged,
pubmed-meshheading:16314618-Myelodysplastic Syndromes,
pubmed-meshheading:16314618-Recurrence,
pubmed-meshheading:16314618-Risk Factors,
pubmed-meshheading:16314618-Stem Cell Transplantation,
pubmed-meshheading:16314618-Survival Analysis,
pubmed-meshheading:16314618-Transplantation, Homologous,
pubmed-meshheading:16314618-Treatment Outcome,
pubmed-meshheading:16314618-Vidarabine
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
|
|
pubmed:affiliation |
Department of Hematology, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
